• Lilly stops promoting cancer drug after shock trial failure pharmaphorum
    January 22, 2019
    Shares in Eli Lilly were down in early trading after the US drugmaker said its cancer drug Lartruvo failed to meet main survival goals in a late stage trial, prompting the company to stop promoting the already-marketed medicine.
PharmaSources Customer Service